Reuters is leading the NTLA stock gene editing race
This was a huge year for the gene-editing giant Intelia Therapeutics (NASDAQ :). The biotech company has received significantly positive results from its recent clinical trials. Accordingly, as a biotech stock, investors may not be surprised to hear that Intelia is one of the best performing stocks in its peer group.
Each year, NTLA stock has risen more than 170%. Over the past year, shares of NTLA stock have risen more than 600%, with investors seeing a steady increase in gene editing.
As a leader in gene editing technology, Intelia has made impressive progress in commercializing its underlying products. It’s got growth gurus like Kathy Wood on board in a big way. And when buying Kathy, you bet retail investors are getting excited.
To date, gene editing companies have used CRISPR-based therapies to edit genetic code in stream cells. Now, Intelia has come up with a technology that captures the COVID-19 vaccine from Biotech (BNTX) and Modern (NASDAQ 🙂 Designed for the potential cure of rare inherited diseases.
Accordingly, NTLA stock is one of the hottest performers lately. It is not surprising that growth has attracted investors in a big way to these potentially disrupted stocks. However, valuation concerns remain as these stocks tend to become more expensive.
At the moment, I am cautiously bullish on NTLA stocks. (See Intellia Therapeutics stock chart at TipRanks)
Future growth drives this stock
Like many high-growth stocks, Intelia is losing money late. In fact, as the market is setting an increased price for this stock in anticipation of a revenue increase, positive earnings are probably a long way off. However, long-term clips that enable Intelia to grow are generally the main focus of investors looking at gene editing stocks. Accordingly, in the long run, investors are betting that the increase in cash flow will be impressive, and more than what will be needed for near-term investment.
That said, Intel’s revenue last year was actually lower than last year. Investors are increasingly looking at clinical trial data compared to past results on Intel’s future growth prospects. Accordingly, it is a stock that seems to be completely detached from its past fundamentals, for good reason.
Let’s see why investors are so laser-focused on recent clinical trial results.
Stimulatory clinical trials
June 2, Intelia and its partner Regeneron Pharmaceuticals (Nasdaq :), give the results of the NTLA-2001 interim test. This is a potential new treatment for ATTR-PN hereditary disease. Patients with this disease experience severe nerve and limb damage when transthyretin begins to break down.
Over time, pieces of transthyretin form dangerous plaques. However, this is not the case with patients receiving NTLA-2001 treatment. Impressive gene therapy by NTLA involves a pair of RNA messengers surrounded by lipid nanoparticles (LNPs). Unlike Aditas candidate, NTLA-2001 reaches the liver safely through the bloodstream.
In the distant past, transmitting RNA safely through the bloodstream seemed like a distant dream. Last year, Biotech and Modern showed that LNP technology has finally evolved and that this is going to be an innovative advancement that everyone was hoping for.
According to recent trial data, a single dose of NTLA-2001 reduced the concentration of transthyretin by less than half. These results were the same for the first three patients who received 0.1 mg / kg of their body weight.
Again, in the next group, patients received a dose of 0.3 mg. This dose reduced the concentration of transthyretin by 87%.
Meanwhile, accidental removal of non-targeted genes is one of the major safety concerns for CRISPR-based companies. However, this has not been a problem for Intelia so far. Of the first six patients receiving NTLA-2001 treatment, no adverse events occurred.
Analysts with NTLA stock
According to TipRanks analysts rating Sens low, Intelia is a strong buy. There are 13 recommendations and 3 recommendations out of 16 ratings.
The average Intelia Therapeutics price target is $ 174.94, which means 17.3% reverse. The analyst price target is low between $ 130 per share and $ 252 per share.
The last row
This interesting trial result has resulted in a record share price increase for NTLA. Indeed, these results are welcomed by long-term investors. Those looking for hyper-growth gene editing stocks with an impressive future are increasingly opting for NTLA stocks. The data suggests that this is the best game in the sector, and the market agrees.
Disclosure: At the time of publication, the securities mentioned in this article by Chris MacDonald had no position.
Disclaimer: The information contained in this article represents the views and opinions of the author only, not the opinions or opinions of Tiprankx or its associates, and should be considered for informational purposes only. TipRanks does not guarantee the completeness, accuracy or reliability of such information. Nothing in this article should be taken as a recommendation or request for the purchase or sale of securities. Nothing in the article constitutes legal, professional, investment and / or financial advice and / or takes into account the specific needs and / or needs of an individual, or any information in the article does not constitute a comprehensive or complete statement of the subject matter. . Tiprankx and its affiliates disclaim all responsibility or liability for the content of the article and any action on the information in the article is at your own and sole risk. The link to this article does not constitute an endorsement or recommendation by TipRanks or its affiliates. Past performance is not an indicator of future results, value or performance.